Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

• 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  Determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies.
• 18F- FDOPA-PET metabolic imaging information [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  Compare radiotherapy target volume delineation with and without 18F- FDOPA-PET metabolic imaging information to determine role of metabolic imaging in radiotherapy treatment planning.

• Correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies [ Designated as safety issue: No ]
• Comparison of radiotherapy target volume delineation with and without 18F-FDOPA-PET metabolic imaging information [ Designated as safety issue: No ]
• Differences in sensitivity and specificity as assessed by McNemar's test [ Designated as safety issue: No ]
• Biopsy validation of 18F-FDOPA-PET uptake and biodistribution in brain tumors [ Designated as safety issue: No ]

• Concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies [ Time Frame: Up to 2 years ] [ Designated as safety issue: No ]
  Determine correlation between concordance of 18F-FDOPA PET and 11C-choline activity, MRI contrast enhancement, and high- or low-grade glioma biopsies and patient outcomes including overall survival and progression free survival.
• With and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
  Compare radiotherapy target volume delineation with and without 18F- FDOPA PET, 11C-choline PET metabolic imaging information; pMRI and DTI advanced MR imaging, to determine role in radiotherapy treatment planning.
• 18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies [ Time Frame: 2 years ] [ Designated as safety issue: No ]
  Determine correlation between 18F-FDOPA PET activity, 11C-choline PET activity, MRI contrast enhancement, pMRI, and DTI, with high- or low-grade glioma biopsies.

RATIONALE: New imaging procedures, such as fluorine F 18 fluorodopa-labeled PET scan, may help in guiding surgery and radiation therapy and allow doctors to plan better treatment.

PURPOSE: This clinical trial studies fluorine F 18 fluorodopa-labeled PET scan in planning surgery and radiation therapy in treating patients with newly diagnosed high- or low-grade malignant glioma

PRIMARY OBJECTIVES:

I. To determine correlation between 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies.

II. To compare radiotherapy target volume delineation with and without 18F- FDOPA-PET metabolic imaging information to determine role of metabolic imaging in radiotherapy treatment planning.

SECONDARY OBJECTIVES:

I. To determine correlation between concordance of 18F-FDOPA PET activity, MRI contrast enhancement, and high- or low-grade glioma biopsies and patient outcomes including overall survival and progression free survival.

OUTLINE:

Beginning at no more than 1 week before biopsy and resection, patients undergo fluorine F 18 fluorodopa-labeled PET/CT scan and pre-operative MRI. Patients then undergo stereotactic craniotomy. Some patients may also undergo radiation therapy.

After completion of study treatment, patients are followed up every year for 5 years.

• Adult Anaplastic Astrocytoma
• Adult Anaplastic Ependymoma
• Adult Anaplastic Oligodendroglioma
• Adult Brain Stem Glioma
• Adult Diffuse Astrocytoma
• Adult Ependymoma
• Adult Giant Cell Glioblastoma
• Adult Glioblastoma
• Adult Gliosarcoma
• Adult Mixed Glioma
• Adult Myxopapillary Ependymoma
• Adult Oligodendroglioma
• Adult Pilocytic Astrocytoma
• Adult Pineal Gland Astrocytoma
• Adult Subependymal Giant Cell Astrocytoma
• Adult Subependymoma

• Procedure: biopsy
  Correlative studies
  Other Name: biopsies
• Procedure: computed tomography
  Undergo computed tomography
  Other Name: tomography, computed
• Procedure: therapeutic conventional surgery
  Undergo stereotactic craniotomy
• Radiation: radiation therapy treatment planning/simulation
  Undergo radiation therapy treatment planning/simulation
• Radiation: radiation therapy
  Undergo radiation therapy
  Other Names:

  • irradiation
  • radiotherapy
  • therapy, radiation
• Procedure: magnetic resonance imaging
  Undergo magnetic resonance imaging
  Other Names:

  • MRI
  • NMR imaging
  • NMRI
  • nuclear magnetic resonance imaging
• Procedure: positron emission tomography
  Undergo positron emission tomography
  Other Names:

  • FDG-PET
  • PET
  • PET scan
  • tomography, emission computed
• Drug: fluorine F 18 fluorodopa
  Given IV
  Other Names:

  • (18)F-FDOPA
  • 18F-6- L-fluorodopa
  • 18F-DOPA
  • 18F-FDOPA

Inclusion Criteria:

• Age ≥18 years.
• MRI findings compatible with newly diagnosed high- or low-grade malignant glioma
• Planned craniotomy and resection or biopsy
• Willing to sign release of information for any radiation and/or follow-up records
• Negative pregnancy test done =< 48 hours of injection of study drug, for women of childbearing potential only
• Provide informed written consent
• Patients with eGFR < 60 mg/min/1.72m2 are eligible for the study; PLEASE NOTE: the patient is not eligible to receive the contrast for the pMRI at the study dose.

Exclusion Criteria:

• Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure)
• Unable to undergo an 18F-FDOPA PET scan (e.g. Parkinson's Disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists)
• Pregnant women; nursing women; men or women of childbearing potential who are unwilling to employ adequate contraception